Home Tags Antibodies

Tag: antibodies

Novasep Invests €17 M in cGMP Facility to Meet Demand for...

Leading services and technologies provider for the life sciences- and pharmaceutical industry, Novasep, is  is investing €17 M in the development of a dedicated...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

TAK-264 (MLN0264) in Previously Treated Patients with Advanced or Metastatic Pancreatic...

Authors: Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC,Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu...

NRC and AvidBiologics Progress In Development of New Antibody-drug Conjugates

Antibody-drug conjugates combine the targeting attributes of antibodies with the cancer destroying properties of drugs that are toxic to cells. Unlike chemotherapy, antibody-drug conjugates specifically seek and destroy cancer cells, with minimal impact on healthy cells.

Engineering Bispecific Antibodies to Cross the Blood-brain Barrier

Over the past decades, the development and regulatory approval of antibody-based therapeutics has progressed rapidly. But poor blood-brain barrier permeability has hampered the progress...

Danish Researchers Develop New Method for Efficient Tagging of Proteins

Researchers at the Aarhus University, Denmark's second oldest university, have developed an easier method to create DNA–protein conjugates. The method can potentially strengthen the work involved in diagnosing diseases. Their findings are published in the July online edition of Nature Chemistry [1]
CPhl worldwide

CPhI Report Sees ADCs as a Key Driver of Tomorrow’s Healthcare

In the first section of the 2013 annual report and industry expert panel, analysts at CPhI Worldwide and CPhI Pharma Evolution describe how they expect that antibody-drug conjugates or ADCs will become a major product group within the oncology market.

Clinical Trial with Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin...

Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the...